Sudeep Pharma Q2 FY26 results: consolidated revenue up 25%, margins expand

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionResults restatedResults View source PDF Explain this filing

SUDEEPPHRM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.9%Reaction day

₹684.00

prior close

₹662.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.4%-4.2% vs market

Specialty Chemicals peers, median of 89sector+0.4%-3.3% vs sector

On the reaction day the stock moved 4.2 pts less than Nifty Microcap 250 and 3.3 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

+0.2

15m

+0.3

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.9+1.4-4.2+0.4-3.3

Next day

-5.7+1.4-7.1+0.9-6.7

-8.6+0.9-9.5+0.4-9.0

-9.2+0.3-9.6+0.7-9.9

-9.1-0.4-8.6-0.2-8.9

-11.1-0.5-10.6-0.3-10.8

-12.7+1.1-13.8+0.3-13.0

15d

-10.4-2.5-7.9-2.8-7.6

-20.6-6.1-14.5-6.8-13.8

-7.3-2.8-4.5-6.6-0.8

-13.6-14.9+1.3-19.0+5.4

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 89Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sudeep Pharma posted first quarterly results after its Nov 28 2025 IPO listing. Consolidated H1 FY26 revenue rose 25.6% YoY to Rs 287.58 crore; PAT grew 18.6% to Rs 78.05 crore. Standalone H1 PAT jumped 30.9% to Rs 54.95 crore. Standalone Q2 revenue dipped 17.3% YoY but margins expanded sharply. EPS was restated for CCPS to equity conversion. Speciality ingredients segment surged.

Likely market impact

First results as a listed company show strong consolidated growth and margin expansion; standalone Q2 dip partly offset by H1 strength.